Renal cell carcinoma in functional renal graft: Toward ablative treatments

Transplant Rev (Orlando). 2016 Jan;30(1):20-6. doi: 10.1016/j.trre.2015.07.001. Epub 2015 Aug 1.

Abstract

The occurrence of a kidney transplant tumor is a rare but serious issue with a double risk: the return to dialysis and the development of metastatic cancer. Publications on this topic are mainly case reports. The purpose of this review was to report an exhaustive literature review of functional graft renal cell carcinomas to highlight the impact of tumors on the renal graft outcomes. 201 de novo renal carcinomas in functional renal grafts from 69 publications were included. Incidence was estimated at 0.18%. Graft tumors were mostly asymptomatic (85.9%). Whatever the discovery circumstances of graft tumors, they were mostly documented by graft ultrasounds supplemented by CT-scanning or MR imaging. Nephron sparing surgery (95 patients) was the first treatment performed followed by radiofrequency ablation (38 patients) and cryotherapy (10 patients). The most common tumor graft histology was clear cell carcinoma (46.4%), followed by papillary carcinoma (43.7%). Specific mortality was 2.9% with 6 deaths. Renal graft cell carcinoma is a rare pathology with a low specific death. When possible, conservative treatment should be the first choice.

Publication types

  • Review

MeSH terms

  • Ablation Techniques*
  • Carcinoma, Renal Cell / etiology
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / surgery*
  • Humans
  • Kidney Neoplasms / etiology
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / surgery*
  • Kidney Transplantation / adverse effects*